Fate Therapeutics appoints Kamal Adawi as CFO, board resignations reduce size from 10 to 8

FATE THERAPEUTICS INC

Kamal Adawi appointed CFO effective Oct 20, 2025; base salary $495k, target bonus 40%.
Adawi receives 375k stock option and 75k RSUs as inducement equity grants, vesting over 4 years.
Board members John Mendlein and Neelufar Mozaffarian resigned voluntarily effective Oct 13, 2025.
Board size decreased from 10 to 8 directors following resignations.
CFO role focused on supporting registrational path for FT819 in SLE and pipeline progress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.